Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€69.50

€69.50

0.000%
-
0.000%
€73.64
 
10:40 / Tradegate WKN: 884113 / Symbol: BSX / Name: Boston Scient / Stock / Healthcare Equipment & Supplies / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Boston Scientific Stock

There is no change in the price for Boston Scientific today.
The stock is an absolute favorite of our community with 49 Buy predictions and no Sell predictions.
As a result the target price of 73 € shows a slightly positive potential of 5.04% compared to the current price of 69.5 € for Boston Scientific.
Criterium "Valuation (undervalued/overvalued)" is seen as the biggest plus for Boston Scientific stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Boston Scientific in the next few years

Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Boston Scientific vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Boston Scientific 0.000% -0.714% 2.206% 45.550% 35.109% 101.976% 104.713%
Waters Corp. -3.460% -7.330% 4.333% 24.344% 0.464% 14.060% 65.810%
QuidelOrtho Corp. 0.000% 3.046% 9.140% -48.634% -40.136% -58.075% -
Illumina Inc. -0.360% -5.019% -18.968% -48.721% -26.661% -71.683% -66.313%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-15

Boston Scientific Corporation (NYSE: BSX) is a prominent player in the healthcare equipment and supplies industry. A review of its financial statements in recent years paints an interesting picture of the company's growth and stability. Initially, it seems that Boston Scientific has experienced a robust increase in total assets and revenue, as indicated in the balance sheet and income statements, which is generally a positive sign for any business. However, a detailed analysis of the company's financials is necessary to better understand its financial health and identify any possible concerns.

*Pros: *

Growth in Total Assets and Total Revenue: Boston Scientific's total assets have been consistently growing year-over-year since 2020, and its total revenue increased from €9.91 billion in 2020 to $12.68 billion in 2022. This growth is indicative of the company's ability to generate business in its niche market and points to a healthy expansion of its operations.

Comments

Prediction Buy
Perf. (%) 0.00%
Target price 87.334
Change
Ends at 28.05.25

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Argus from $80.00 to $95.00. They now have a "buy" rating on the stock.
Ratings data for BSX provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 0.00%
Target price 80.266
Change
Ends at 22.05.25

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Citigroup Inc. from $85.00 to $87.00. They now have a "buy" rating on the stock.
Ratings data for BSX provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 1.46%
Target price 82.854
Change
Ends at 15.05.25

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Mizuho from $85.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for BSX provided by MarketBeat
Show more